Dr. Ai on the FDA Approval of Mogamulizumab in CTCL
August 8th 2018Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Read More